Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425323 | 0.86 | LMNA (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19TDP1 | |
| SCHEMBL3428392 | 0.81 | L3MBTL1 (0.61) | TDP1L3MBTL1 | |
| SCHEMBL3423447 | 0.81 | L3MBTL1 (0.76) | TDP1L3MBTL1HTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27582483 | 0.77 | CARM1 (0.58) | CYP1A2CYP3A4CYP2C19L3MBTL1HTT | |
| SCHEMBL8985647 | 0.76 | MEN1 (0.51) | CYP3A4CYP2D6CYP2C19HTTCARM1 | |
| SCHEMBL28039903 | 0.73 | CYP3A4 (0.97) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27702461 | 0.73 | CARM1 (0.64) | CYP1A2CYP3A4CYP2C19CARM1PRMT1 | |
| SCHEMBL5646043 | 0.73 | ENPP2 (0.62) | CYP1A2CYP3A4CYP2C19CARM1PRMT1 | |
| SCHEMBL13388600 | 0.72 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19TDP1 | |
| SCHEMBL21844358 | 0.72 | GAA (0.60) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | claimed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | claimed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | claimed |
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | disclosed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | HTR7, MAOB, CYP2A7 | CYP1A2 124/4885CYP3A4 270/4885CYP2D6 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.